- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06900192
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Um estudo multicêntrico de fase 1 do transplante de células hematopoiéticas alogênicas para esclerose múltipla progressiva primária usando orca-q, um enxerto de doador de engenharia derivado do sangue periférico mobilizado
A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: James S. McClellan, MD, PhD
- Número de telefone: 650-246-9601
- E-mail: info@orcabio.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria (Recipient):
-
Participants aged ≥18 and ≤65 years with PPMS
a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision
-
Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
-
EDSS between 2.0 and 5.5 inclusive
-
Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)
-
Eligibility criteria confirmed by the Eligibility Review Group
-
Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0
-
Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT
-
Willing to undergo MAC preparative regimen
-
Matched to either a related or unrelated donor as follows:
- Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
- Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
-
Negative serum or urine β-HCG test in persons of childbearing potential
Exclusion Criteria:
-
History of Progressive Multifocal Leukoencephalopathy
-
Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:
- Renal insufficiency as defined by an estimated GFR <60 mL/minute
- Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
- Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
- Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
- Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
- Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
- Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
- Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
-
History of smoking either tobacco or other herbal products in the last 3 months
-
Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol
-
HIV seropositive
-
HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant
-
HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy
-
Participant has active uncontrolled infection
-
Participant has demonstrated lack of compliance with prior medical care
-
Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.
-
Participants whose life expectancy is severely limited by illness other than multiple sclerosis
-
Females who are pregnant or breast feeding
-
Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol
-
Inability to undergo an MRI scan
-
Currently receiving treatment with investigational agents
-
Positive for JC virus DNA in the CSF or blood during screening
-
Known allergy or hypersensitivity to or intolerance of tacrolimus
-
Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
-
Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:
- Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
- Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
-
People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Orca-Q Graft with myeloablative conditioning regimen
Donor Orca-Q stem cell graft |
Allogeneic (donor) stem cell graft Myeloablative regimen of busulfan, fludarabine, and thiotepa.
Outros nomes:
Graft-versus-host disease (GVHD) prevention |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Severe acute graft-versus-host-disease-free survival
Prazo: Up to 6 months after infusion
|
Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse) |
Up to 6 months after infusion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Event-Free Survival (EFS)
Prazo: Up to 24 months and at year 5 after Orca-Q infusion
|
Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death |
Up to 24 months and at year 5 after Orca-Q infusion
|
|
Loss of Neurological Function or Relapse
Prazo: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse |
Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
|
Overall Survival (OS)
Prazo: From transplant through 5 years after transplant
|
Time in years from transplant to death from any cause |
From transplant through 5 years after transplant
|
|
Treatment-Related Mortality (TRM)
Prazo: From start of alloHCT through 5 years after transplant
|
Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data |
From start of alloHCT through 5 years after transplant
|
|
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
Prazo: From Orca-Q infusion through 5 years after transplant
|
Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded |
From Orca-Q infusion through 5 years after transplant
|
|
Incidence of aGVHD
Prazo: From transplant through 5 years after transplant
|
Number of participants with aGVHD |
From transplant through 5 years after transplant
|
|
Severity of aGVHD
Prazo: From transplant through 5 years after transplant
|
Severity is graded per MAGIC criteria |
From transplant through 5 years after transplant
|
|
Incidence chronic graft-versus-host disease (cGVHD)
Prazo: From transplant through 5 years after transplant
|
Number of participants with cGVHD |
From transplant through 5 years after transplant
|
|
Severity of cGVHD
Prazo: From transplant through 5 years after transplant
|
cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD |
From transplant through 5 years after transplant
|
|
Incidence of Primary Graft Failure
Prazo: Through day +28
|
Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause |
Through day +28
|
|
Incidence of Secondary Graft Failure
Prazo: Through day +100
|
Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause |
Through day +100
|
|
Time to Neutrophil Engraftment
Prazo: From transplant through Day +365
|
Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days. |
From transplant through Day +365
|
|
Development of Infectious Complications
Prazo: From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation |
From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
|
Regimen-Related Toxicity
Prazo: From start of conditioning through 1 year after transplant
|
Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse). |
From start of conditioning through 1 year after transplant
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Processos Patológicos
- Doença crônica
- Atributos da doença
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças Autoimunes Desmielinizantes, SNC
- Doenças Autoimunes do Sistema Nervoso
- Doenças Desmielinizantes
- Condições Patológicas, Sinais e Sintomas
- Esclerose múltipla
- Esclerose Múltipla Progressiva Crônica
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Hidrocarbonetos, acíclico
- Hidrocarbonetos
- Alcans
- Álcoons
- Butileno glicols
- Glicols
- Mesilatos
- Alkanesulfonatos
- Ácidos alcanesulfônicos
- Ácidos sulfônicos
- Ácidos de enxofre
- Macrolídeos
- Lactonas
- Fosforamidas
- Compostos organofosforos
- Trietilenefosforamida
- Aziridinas
- Azirines
- Tacrolimo
- Bussulfano
- Tiotepa
- fludarabina
Outros números de identificação do estudo
- OQ PPMS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .